Responsibility for planning and evaluation is vested in the Lombardi Comprehensive Cancer Center (Lombardi) Director. Planning and evaluation was previously managed by the Associate Director for Administration and Planning (ADAP), with input from the Shared Resources (SRs) Director and programmatic reviews by Program Leadership and the Executive Committee. Following a strategic planning process in 2008, the Director and the Senior Operational Leadership Team (SOLT) now oversee the current planning and evaluation process, with advice from the Associate Directors, the Program Leaders, the Executive Advisory Committee (EAC) and the External Scientific Advisory Committee (ESAC). This has led to changes in several programs and shared resources. At the time of the last competitive CCSG renewal, the Cancer Center Director relied upon the Lombardi Executive Committee for the oversight of Cancer Center activities. This large Committee generally met weekly with the Director to discuss and coordinate scientific recruitment and administrative activities. With the arrival of Dr. Weiner, two new Senior Leadership positions were established, which specifically Include the tasks of planning and evaluation. Dr. Peter Shields was appointed as Deputy Director, and V. Craig Jordan joins Lombardi on July 1, 2009 as Scientific Director. Dr. Weiner separated the functions of the single Executive Committee Into the SOLT and EAC. The SOLT consists of Drs. Weiner, Shields (Deputy Director), Jordan (effective July 1, in his role as Scientific Director), Marshall (Clinical Director), and Mr. Michael Vander Hoek (Associate Director for Administration and Planning). This group meets weekly to address all operational Issues that affect the Cancer Center. The EAC was established to strengthen inter-departmental and transdisciplinary collaborations and to receive important operational feedback that can contribute to the success of the Cancer Center. The EAC meets quarterly. This committee includes a representative from Georgetown University Hospital (GUH) administration, the Department Chairs in the Lombardi Sector, all of whom have an undiluted cancer focus, and other cancer-related departments that reside within GUMC. Dr. Weiner also established regular meetings of the Associate Directors (ADs), who meet monthly to review the progress of Lombardi in the context of the CCSG, conduct planning and evaluation of Lombardi activities, oversee developmental funds, and foster collaborations across programs and disciplines. As before. Program Leaders also meet monthly to provide the SOLT with Lombardi updates and receive feedback on Lombardi activities, vet new Lombardi membership, review Program membership, review shared resource activities, and discuss new collaborative activities. In response to a formal strategic planning process in 2008, six programs and 12 shared resources were reconfigured and identified. This effort led to the identification of cross-cutting initiatives, the redefinition of each programs'aims, recruitment plans, and prioritization of resource allocation. Future plans include fostering transdisciplinary, multi-investigator research, emphasizing cross-cutting initiatives such as minority and health disparities research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA051008-20
Application #
8739839
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-15
Project End
2014-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
20
Fiscal Year
2013
Total Cost
$14,874
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Bae, Woo Kyun; Yoo, Kyung Hyun; Lee, Ji Shin et al. (2015) The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers. Mol Carcinog 54:1172-80
Adams, Inez; Christopher, Juleen; Williams, Karen Patricia et al. (2015) What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2. J Cancer Educ 30:344-52
Butrick, Morgan; Kelly, Scott; Peshkin, Beth N et al. (2015) Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. Genet Med 17:467-75
London, Laricca; Hurtado-de-Mendoza, Alejandra; Song, Minna et al. (2015) Motivators and barriers to Latinas' participation in clinical trials: the role of contextual factors. Contemp Clin Trials 40:74-80
Mays, Darren; Niaura, Raymond S; Evans, W Douglas et al. (2015) Cigarette packaging and health warnings: the impact of plain packaging and message framing on young smokers. Tob Control 24:e87-92
Zhi, Xiuling; Lin, Ling; Yang, Shaoxian et al. (2015) ?II-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology 61:598-612
Rush, Christina L; Darling, Margaret; Elliott, Maria Gloria et al. (2015) Engaging Latina cancer survivors, their caregivers, and community partners in a randomized controlled trial: Nueva Vida intervention. Qual Life Res 24:1107-18
Heckler, Mary Mazzotta; Riggins, Rebecca B (2015) ERR? splice variants differentially regulate cell cycle progression. Cell Cycle 14:31-45
Kim, B; Wang, S; Lee, J M et al. (2015) Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 34:1083-93
Tong, Angie; Kelly, Scott; Nusbaum, Rachel et al. (2015) Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psychooncology 24:33-9

Showing the most recent 10 out of 544 publications